Grid Oasis
S&P 500NASDAQ 100Dow JonesRussell 2000All StocksSectors & Industries

GRAL

+ Watchlist+ Portfolio

GRAIL, Inc.

Regulated industryTags from an AI model reading the company description.
GridBrain

GridBrain — Sign in

GridSentinel

GridSentinel — Sign in

GridAegis

GridAegis — Sign in

Key Metrics

Previous Close
$105.88
52-Week Range
$41.50 – $166.48
Market Cap
$4.59B
P/E (TTM)
—
EPS (TTM)
-9.22
Dividend Yield
0.00%
Advanced Metrics
Price/Book
1.86
PEG Ratio
—
Return on Equity
-17.31%
Return on Assets
-12.97%
Gross Margin
46.68%
Operating Margin
-332.04%
Profit Margin
-243.80%
Current Ratio
8.93
Debt/Equity
0.03
Total Debt
$85.85M
Free Cash Flow
$-112.64M
Revenue Growth
3.70%
Earnings Growth
—
Enterprise Value
$3.89B

Market Snapshot

About

GRAIL, Inc. operates as a healthcare company focused on early cancer detection through blood testing technology. Headquartered in Menlo Park, California, the company develops and commercializes multi-cancer early detection tests using next-generation sequencing and machine learning algorithms. GRAIL's flagship product, Galleri, is a blood-based screening test designed to detect multiple types of cancer, many of which lack standard screening methods, often before symptoms appear. The test analyzes cell-free DNA in the bloodstream to identify cancer signals and predict the tissue of origin. The company was founded in 2016 as a spin-off from Illumina, Inc., which later reacquired GRAIL in 2021 for approximately $7.1 billion, though the acquisition faced significant regulatory scrutiny from the Federal Trade Commission and European Commission. In 2023, following an FTC order, Illumina began the process of divesting GRAIL as a separate entity. GRAIL employs over 1,500 people and operates laboratories and offices across the United States and internationally. The company targets healthcare providers, health systems, and self-pay consumers, positioning its technology as a complement to existing single-cancer screening programs. GRAIL continues to conduct clinical studies and pursue regulatory pathways while expanding commercial availability of its testing services in select markets.